NCT07072611View on ClinicalTrials.gov

Clinical Trial to Evaluate Safety, Tolerability, and Pharmacokinetics of SOF-SKN in Healthy Participants

EARLY_PHASE1RecruitingINTERVENTIONAL
Enrollment

32

Participants

Timeline

Start Date

July 14, 2025

Primary Completion Date

February 28, 2026

Study Completion Date

March 31, 2026

Conditions
Cutaneous Lupus Erythematosus
Interventions
DRUG

SOF-SKN 0.25%

cream for topical application

DRUG

SOF-SKN 0.5%

cream for topical application

DRUG

SOF-SKN 1%

cream for topical application

DRUG

SOF-SKN 2%

cream for topical application

DRUG

Placebo

cream for topical application

Trial Locations (1)

Unknown

RECRUITING

Doherty Clinical Trials, Melbourne

Sponsors

Lead Sponsor

Noxopharm Limited
All Listed Sponsors
lead

Noxopharm Limited

INDUSTRY